For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive AphasiaGil-Navarro S.a · Lladó A.a, d · Rami L.a · Castellví M.a · Bosch B.a · Bargalló N.b, d · Lomeña F.c · Reñé R.e · Montagut N.a · Antonell A.a, d · Molinuevo J.L.a, d · Sánchez-Valle R.a, d
aAlzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, and Departments of bRadiology and cNuclear Medicine, Hospital Clínic, and dInstitut d’Investigació Biomédica August Pi I Sunyer (IDIBAPS), Barcelona, and eDepartment of Neurology, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Spain
Background/Aim: To investigate in variants of primary progressive aphasia (PPA) the association between current clinical and neuroimaging criteria and biochemical/genetic markers at the individual level. Methods: Thirty-two PPA patients were classified as non-ﬂuent/agrammatic (nfvPPA), semantic (svPPA), or logopenic variant (lvPPA) or as unclassifiable (uPPA). In all patients, we evaluated the neuroimaging criteria (magnetic resonance imaging and/or single photon emission computed tomography/positron emission tomography) of each variant and studied serum progranulin levels, APOE genotype and Alzheimer’s disease (AD)-cerebrospinal fluid (CSF) biomarkers. Cases with a first-degree family history of early-onset dementia were genetically tested. Results: Ten of 15 (66%) nfvPPA, 5/5 (100%) svPPA and 7/7 (100%) lvPPA patients showed at least one positive neuroimaging-supported diagnostic criterion. All lvPPA and 3/5 (60%) uPPA patients presented AD-CSF biomarkers, which were absent in nfvPPA and svPPA cases. Four (27%) nfvPPA patients had dementia-causing mutations: 2 carried a GRN mutation and 2 the C9ORF72 hexanucleotide expansion. Conclusions: There was an excellent association between clinical criteria and neuroimaging-supported biomarkers in svPPA and lvPPA, as well as with AD-CSF biochemical markers in the lvPPA. Neuroimaging, biochemical and genetic findings in nfvPPA were heterogeneous. Incorporating biochemical/genetic markers into the PPA clinical diagnosis would allow clinicians to improve their predictions of PPA neuropathology, especially in nfvPPA and uPPA cases.
© 2013 S. Karger AG, Basel